[Taktivin treatment of immunologic disorders in patients with nonspecific ulcerative colitis].
Nonspecific ulcerative colitis (NSUC) varying in severity was treated by conventional methods (49 patients) against combined treatment including tactivin (93 patients). All the patients were examined immunologically at admission and in the course of the treatment. The drug produced a positive effect on immunological status, treatment effectiveness rose, NSUC exacerbations rapidly attenuated.
Shafer
N P
NP
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D013949:Thymus Extracts / Q000008:administration & dosage / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D010455:Peptides; D013949:Thymus Extracts; C036191:T-activin
Korrektsiia taktivinom immunnykh narusheniĭ u bol'nykh nespetsificheskim iazvennym kolitom.